Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study

REFERENCES

• Murphy RL, Montaner J. Nevirapine: a review of its devel-opment, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs. 1996;5(9):1183–1199.
   Google Scholar
• Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279(12):930–937.
   PubMed Web of Science ®Google Scholar
• Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther. 2000;5(4):267–272.
   PubMed Web of Science ®Google Scholar
• Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS. 2000; 14(16):2485–2494.
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Katlama C, Murphy RL, et al. A random-ized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17(7):987–999.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collabora-tive Treatment Group. AIDS. 1999;13(9):1099–1107.
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–1263.
   PubMed Web of Science ®Google Scholar
• Kappelhoff BS, Rosing H, Huitema ADR, Beijnen JH. Simple and rapid method for the simultaneous determina-tion of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life ScL 2003;792(2):353–362.
   PubMed Web of Science ®Google Scholar
• Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther. 2005;10(1):145–155.
   PubMed Web of Science ®Google Scholar
• Beal S, Sheiner L. NONMEM User's Guides. NONMEM Project Group. San Francisco: University of California at San Francisco; 1998.
   Google Scholar
• Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on pa-tient medication compliance. Arch Intern Med. 1990;150(9)1 881–1884.
   Google Scholar
• Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34(2):191–194.
   PubMed Web of Science ®Google Scholar
• Hawkins T. Impact of once- and twice-daily dosing regi-mens on adherence and overall safety. AIDS Read. 2004;14(6):320–335.
   PubMedGoogle Scholar
• Kappelhoff BS, van Leth F, Robinson PA et al. Are adverse events related with plasma concentrations of nevirapine and efavirenz? Antivir Ther. 2005;10(4):489–498.
   PubMed Web of Science ®Google Scholar
• van Leth F, Kappelhoff B, Johnson D, et al., and the 2NN Study group. Minimum plasma concentrations of nevirapine and efavirenz in relation to virologic failure in antiretroviral-naive patients. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston. Abstract 80.
   Google Scholar
• van Heeswijk RPG, Veldkamp Al, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14(8):F77—F82.
   PubMed Web of Science ®Google Scholar
• Veldkamp Al, Weyerling GJ, Lange JMA, et al. High expo-sure to nevirapine in plasma is associated with an im-proved virological response in HIV-1-infected individuals. AIDS. 2001;15(9)1 089–1095.
   Web of Science ®Google Scholar
• de Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003 ; 42 (6): 599–605 .
   PubMed Web of Science ®Google Scholar
• Bonora S, Gonzalez de Requena D, Garazzino S, et al. Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time of maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens. In: Program and abstracts of the 5th Interna-tional Workshop on Clinical Pharmacology of HIV Therapy; April 1–3, 2004; Rome. Abstract 6.10.
   Google Scholar
• Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171(3):537–545.
   PubMed Web of Science ®Google Scholar
• Cheeseman SH, Hattox SE, McLaughlin MM, et al. Phar-macokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother. 1993;37(2): 178–182.
   PubMed Web of Science ®Google Scholar
• Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS. 2002;16(2):290–291.
   PubMed Web of Science ®Google Scholar
• de Maat MMR, ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol. 2003;59(5-6):457–462.
   PubMed Web of Science ®Google Scholar
• de Maat MMR, Mathôt RAA, Veldkamp Al, et al. Hepato-toxicity following nevirapine-containing regimens in HIV-1-infected individuals. Pharmacol Res. 2002;46(3):295–300.
   PubMed Web of Science ®Google Scholar
• Sarasa M, Mir6 JM, Knobel H, et al. Nevirapine plasma levels at two weeks neither predicts nevirapine-associated rash nor liver toxicity. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1–3, 2004; Rome. Abstract 6.5.
   Google Scholar
• EMEA public statement on Viramune (nevirapine) - severe and life-threatening cutaneous and hepatic reactions (Lon-don, 12 April 2000, EMEA/11260/00). Available at: http://www.emea.eu.inf/pdfs/human/press/pus/1126000EN.pdf.
   Google Scholar